Recent Development of Anticancer Therapeutics Targeting Akt
- 1 January 2011
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Recent Patents on Anti-Cancer Drug Discovery
- Vol. 6 (1) , 146-159
Abstract
The serine/threonine kinase Akt has proven to be a significant signaling target, involved in various biological functions. Because of its cardinal role in numerous cellular responses, Akt has been implicated in many human diseases, particularly cancer. It has been established that Akt is a viable and feasible target for anticancer therapeutics. Analysis of all Akt kinases reveals conserved homology for an N-terminal regulatory domain, which contains a pleckstrin-homology (PH) domain for cellular translocation, a kinase domain with serine/threonine specificity, and a C-terminal extension domain. These well defined regions have been targeted, and various approaches, including in silico methods, have been implemented to develop Akt inhibitors. In spite of unique techniques and a prolific body of knowledge surrounding Akt, no targeted Akt therapeutics have reached the market yet. Here we will highlight successes and challenges to date on the development of anticancer agents modulating the Akt pathway in recent patents as well as discuss the methods employed for this task. Special attention will be given to patents with focus on those discoveries using computer-aided drug design approaches.Keywords
This publication has 85 references indexed in Scilit:
- Molecular Pharmacology and Antitumor Activity of PHT-427, a Novel Akt/Phosphatidylinositide-Dependent Protein Kinase 1 Pleckstrin Homology Domain InhibitorMolecular Cancer Therapeutics, 2010
- Chain termination and inhibition of mammalian poly(A) polymerase by modified ATP analoguesBiochemical Pharmacology, 2010
- Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domainBioorganic & Medicinal Chemistry, 2009
- Inhibition of ATP synthase by chlorinated adenosine analogueBiochemical Pharmacology, 2009
- The E3 Ligase TRAF6 Regulates Akt Ubiquitination and ActivationScience, 2009
- AKT-Independent Signaling Downstream of Oncogenic PIK3CA Mutations in Human CancerCancer Cell, 2009
- In vitro and In vivo Activity of Novel Small-Molecule Inhibitors Targeting the Pleckstrin Homology Domain of Protein Kinase B/AKTCancer Research, 2009
- Discovery of a novel class of AKT pleckstrin homology domain inhibitorsMolecular Cancer Therapeutics, 2008
- Antitumor Agents 252. Application of validated QSAR models to database mining: discovery of novel tylophorine derivatives as potential anticancer agentsJournal of Computer-Aided Molecular Design, 2007
- A Novel Automated Lazy Learning QSAR (ALL-QSAR) Approach: Method Development, Applications, and Virtual Screening of Chemical Databases Using Validated ALL-QSAR ModelsJournal of Chemical Information and Modeling, 2006